The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine (Q46515116)

From Wikidata

Jump to navigation Jump to search

scientific article published in August 2005

Language	Label	Description	Also known as
English	The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine	scientific article published in August 2005

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

The Ca2+-sensitizer levosimendan improves oxidative damage, BNP and pro-inflammatory cytokine levels in patients with advanced decompensated heart failure in comparison to dobutamine (English)

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

0 references

1 reference

based on heuristic

inferred from title

author name string

Catherine Avgeropoulou

1

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

Ioanna Andreadou

2

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

Sophia Markantonis-Kyroudis

3

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

Maritina Demopoulou

4

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

Platon Missovoulos

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

Aris Androulakis

6

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

Ioannis Kallikazaros

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

publication date

1 August 2005

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

European Journal of Heart Failure

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

7

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

5

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

882-887

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

Chronic heart failure: an example of a systemic chronic inflammatory disease resulting in cachexia

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Different secretion patterns of atrial natriuretic peptide and brain natriuretic peptide in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Measurement and importance of plasma brain natriuretic peptide and related peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

A glossary of circulating cytokines in chronic heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

The role of tumor necrosis factor in the pathophysiology of heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Interleukin-6 spillover in the peripheral circulation increases with the severity of heart failure, and the high plasma level of interleukin-6 is an important prognostic predictor in patients with congestive heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Plasma lipophilic antioxidants and malondialdehyde in congestive heart failure patients: relationship to disease severity

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Stereoselective binding of levosimendan to cardiac troponin C causes Ca2+-sensitization

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Binding of levosimendan, a calcium sensitizer, to cardiac troponin C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Reduction of myocardial infarct size in rabbits by a novel indole derivative with antioxidant and free radical scavenging properties

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Melatonin does not prevent the protection of ischemic preconditioning in vivo despite its antioxidant effect against oxidative stress

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Evaluation of impaired left ventricular ejection fraction and increased dimensions by multiple neurohumoral plasma concentrations.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Heart failure and neuroendocrine activation: diagnostic, prognostic and therapeutic perspectives

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT.

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Neurohumoral prediction of benefit from carvedilol in ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Use of BNP levels in monitoring hospitalized heart failure patients with heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone trial (VEST).

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Effects of levosimendan on circulating pro-inflammatory cytokines and soluble apoptosis mediators in patients with decompensated advanced heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Heart failure, redox alterations, and endothelial dysfunction

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Pharmacodynamics and safety of a new calcium sensitizer, levosimendan, and its metabolites during an extended infusion in patients with severe heart failure

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Sustained hemodynamic effects of intravenous levosimendan

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD)

1 reference

https://api.crossref.org/works/10.1016%2FJ.EJHEART.2005.02.002

21 January 2018

Identifiers

10.1016/J.EJHEART.2005.02.002

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

22 December 2017

http://europepmc.org/abstract/MED/15921958

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q46515116&oldid=2115653567"